Special event note: Due to the prolonged pandemic, we have decided to postpone the SLAS 2020 Building Biology in 3D Symposium. The health and well-being of our attendees are at the center of our concerns and we feel that postponing this event until it can be conducted safely is the best course of action at this time. We will reschedule for the latter half of 2021 and look forward to seeing you in person once again!
This year's SLAS Building Biology in 3D Symposium features sessions in the following topics.
Enabling Technologies: This session centers on innovations in 3D culture enabling technologies. New functional and biology-inspired interfaces (think SynBio) and polymer networks and their impact on 3D culture will be presented. Learn how phase transition and its utility as a tool in synthetic biology can create artificially high concentrations of enzymes and substrates via coacervation. Recent developments in synthetic, natural hydrogels and matrix-free technologies for embedding 3D cultures are discussed including scalability for larger applications will also be discussed. Lastly, state-of-the-art organ-on-chip platforms will be presented and their application perspective relative to 3D culture systems will be discussed.
High-Throughput Advanced Cellular Models: This session will explore complex cellular screening platforms, including the adoption of novel technologies and multivariant approaches to enable implementation of effective screening campaigns and hit triage strategies to identify, validate and characterize disease-relevant targets.
Advances in Imaging and Analysis: Imaging modalities and imaging modes are currently the domain of a few specialists worldwide. Explore how these systems work and learn how to adapt them for when they become accessible to the broader research community in the coming years.
Complex Translational Models: With rapid advances in three-dimensional (3D) culture methods, scientists have modeled many complex human diseases in a dish. Cultures can incorporate both disease cells as well as key microenvironmental compartments. These patient-derived translational models are amenable to phenotypic screening enabling scientists to empirically identify effective therapeutic options and novel biomarkers ex-vivo. Early results suggest that findings in 3D models translate to patient outcomes. In this session, attendees will hear from experts who are optimizing robust platforms to empower clinicians and patients to take advantage of complex 3D translational models.